Replies to post #20 on Lobe Sciences Ltd. (LOBEF)

[Walker]

Eleusian is a private company focused on the development of medical devices and therapeutics for specific
diseases. It is collaborating with a multidisciplinary team of scientists and physicians at the Miller School
of Medicine at the University of Miami to develop effective therapeutics for the treatment of mild traumatic
brain injury/concussion (“mTBI”) with post-traumatic stress disorder (“PTSD”) or PTSD alone, using
psilocybin and N-Acetylcysteine (“NAC”). NAC has been shown to be safe and efficacious in a phase I
human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to
demonstrate the efficacy of the combination of psilocybin and NAC in the treatment of mTBI with PTSD
in established rodent models. The research team at the Miller School of Medicine has a license from the
United States Drug Enforcement Administration to conduct research using Schedule I controlled
substances, which includes psilocybin.
The Eleusian management team includes seasoned capital markets and life sciences executives. CEO and
director, Jonathan Gilbert, had a successful prior exit in the psychedelic space and was the CEO of Scythian
Biosciences, Inc., a publicly traded research and development company focusing on the prevention and
treatment of concussions and traumatic brain injury using a proprietary cannabinoid combination. Mr.
Gilbert is also experienced in strategic investments and partnerships related to the cultivation, distribution
and retail sale of legal cannabis.
Maghsoud Dariani, Chief Science Officer, has years of expertise with life sciences companies. He is
currently also President and CEO of Semorex Inc., a privately held company focused on the discovery and
development of novel therapeutics for cancer. Prior to joining Semorex, Mr. Dariani was President of Focus
Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving an
FDA approval and bringing another to the clinical evaluation stage. He subsequently negotiated the
successful sale of the company in February 2003. Prior to Focus, Mr. Dariani was Vice President of the
chiral pharmaceutical business unit at Celgene Corporation. During histwelve years at Celgene, Mr. Dariani
was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin,
which are currently marketed by Novartis under the Focalin and Focalin XR trade names.

[Walker]

Big bidder at .062 and buys at .065 now - looking good.

[Walker]

GreenStar Biosciences Announces Filing of Third Provisional Patent Application by Eleusian Biosciences
Newsfile Corp.
Newsfile Corp
Additional provisional patent application, strengthens IP portfolio of therapeutics for the treatment of mild traumatic brain injuries (mTBI) with PTSD or PTSD alone.

Vancouver, British Columbia--(Newsfile Corp. - July 23, 2020) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company") is pleased to announce that Eleusian Biosciences Corporation ("Eleusian") has added to its existing intellectual property portfolio by filing a third provisional patent application. This application further expands the portfolio of proprietary psychedelic therapeutics available to GreenStar and strengthens the intellectual property ("IP") portfolio for treatment of neuropsychiatric disorders with psychedelic compounds. As announced on July 21, 2020, GreenStar and Eleusian have entered into a binding definitive share exchange agreement for GreenStar to acquire 100% of Eleusian.

This provisional patent application Serial No.: 63/040,032 is for methods and compositions for treating mild traumatic brain injury/concussion ("mTBI") with post-traumatic stress disorder ("PTSD") or PTSD alone with 3,4-methylenedioxymethamphetamine ("MDMA") plus N-acetylcysteine ("NAC").

In 2017, the United States Food and Drug Administration ("FDA") granted breakthrough therapy designation for MDMA-assisted psychotherapy for the treatment of PTSD. The Multidisciplinary Association for Psychedelic Studies ("MAPS"), has already successfully completed Phase 2 clinical trials for MDMA-assisted psychotherapy for PTSD, where of 107 participants, 68% no longer had PTSD at the 12-month follow up. All participants had chronic treatment-resistant PTSD and had suffered from PTSD for an average of 17.8 years. (https://maps.org/research/mdma/ptsd/phase3). MAPS has obtained the FDA's agreement for an Expanded Access program, which will allow early access to potentially beneficial investigational therapies for people facing a serious or life-threatening condition for whom currently available treatments have not worked, and who are not able to participate in Phase 3 clinical trials. These agreements validate the fact that MDMA can be an effective therapeutic option for people suffering from PTSD. Eleusian management believes their combination of MDMA plus NAC will result in superior efficacy relative to MDMA alone.

As previously announced, Eleusian has a collaboration agreement with the Miller School of Medicine at the University of Miami to work with a multidisciplinary team of scientists and physicians to develop effective therapeutics for the treatment of mTBI with PTSD, or PTSD alone, using psilocybin and NAC. NAC has been shown to be safe and efficacious in a phase I human clinical study treating military personnel who had suffered mTBI. Eleusian intends to discuss with the Miller School of Medicine at the University of Miami the potential to initiate a research program with their same research team studying MDMA plus NAC for the treatment of mTBI with PTSD or PTSD alone.

According to the Centers of Disease Control and Prevention (the "CDCP"), traumatic brain injury ("TBI") is a major cause of death and disability in the United States. According to the CDCP, the number of TBI-related emergency department visits, hospitalizations, and deaths increased by 53% from 2006 to 2014. TBI cases can range from mild to severe. Mild TBI is the most prevalent form of TBI and effects can include physical symptoms such as loss of consciousness, headache, nausea, fatigue, dizziness and others, sensory problems such as blurred vision, ringing in the ears and sensitivity to light and sound, and cognitive or mental symptoms such as memory problems, mood changes and feelings of depression. These issues not only affect individuals with TBI, but can also have lasting effects on families and communities. According to the U.S. Department of Veterans Affairs, National Center for PTSD, about 7-8% of the U.S. population will have PTSD at some point in their lives and about 8 million U.S. adults have PTSD during a given year. PTSD is a mental health condition that can affect anyone, with potentially long lasting effects. PTSD and TBI have similar symptoms and often coexist because brain injuries are often sustained in traumatic experiences and there is increasing evidence that mTBI can increase risk for PTSD.

"The goal at Eleusian has been to create a best in class management and scientific team, develop our IP portfolio, and develop medical devices and therapeutics to treat certain brain diseases and promote mental wellness," said Maghsoud Dariani, CSO of Eleusian. "With the success MAPS has been having, we are very excited to add the new provisional patent application using MDMA to our portfolio of intellectual property. The research and use of psychedelics, for the treatment of brain injury, has been gaining significant traction and support recently. With our in-house expertise and collaboration partners at the Miller School of Medicine, we believe our development efforts can result in a groundbreaking treatment for mTBI with PTSD or PTSD alone."

About GreenStar

GreenStar is a growth-oriented technology & services company that provides real estate, financial, management, IP & branding support to businesses. The Company operates a growing portfolio of tenant partner companies focused on developing transformational medicines and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies by leveraging its capital markets, branding and operational expertise.

About Eleusian

Eleusian Biosciences Corp., a Toronto based company, is focused on development of therapeutics for multiple pathological psychological diseases based on psychedelic compounds including psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) plus N-Acetylcysteine (NAC) compounds. Eleusian is collaborating with a multidisciplinary team of scientists and physicians at the Miller School of Medicine at the University of Miami to develop effective therapeutics for the treatment of mTBI (mild traumatic brain injury/concussion) with PTSD or PTSD alone based on Psilocybin (the active ingredient of psychedelic mushrooms) and NAC or MDMA and NAC. NAC has been shown to have efficacy in treating mTBI, particularly in reducing neuronal losses and also reducing impaired cognitive and neurological symptoms after injury to head. For more information, visit the company's website at www.eleusian.bio.